stars 1 stars 2 stars 3

Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammi’s lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.

View Top Employees from Nammi Therapeutics, Inc.

Nammi Therapeutics, Inc. Questions

The Nammi Therapeutics, Inc. annual revenue was $200000 in 2024.

Joseph Rice is the Executive Vice President of Operations of Nammi Therapeutics, Inc..

6 people are employed at Nammi Therapeutics, Inc..

Nammi Therapeutics, Inc. is based in Los Angeles, California.

The NAICS codes for Nammi Therapeutics, Inc. are [5417, 54171, 54, 541, 541714].

The SIC codes for Nammi Therapeutics, Inc. are [87, 873].

Top Nammi Therapeutics, Inc. Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users